Probiotic strain for the prevention and management of Diabetes-related conditions - Genbioma

Preclinical Relevance of Pediococcus acidilactici​ CECT 9879 (pA1c®) for the Prevention of Diabetes-Related Conditions. ​

Please click on the PDF link below in order to view or download the study. ​

Objective

The present review shows our most recent results aimed to investigate the normoglycemic activity of the probiotic Pediococcus acidilactici​ CECT9879 (pA1c®), either alone or in combination with bioactive compounds or drugs such as metformin.

Method

Genbioma's proprietary and patented bacterial strain pA1c® was evaluated. The preclinical trials were run with N2-Bristol- and insulin-signaling-null-mutants of Caenorhabditis elegans and murine models of PreD, T2D and GestationalD. The anti-diabetic effectivity of the strain was studied in a high-sucrose-diets enriched with either pA1c® alone, or combined with chromium picolinate (PC) and oat-β-glucans (BGC), metformin, or placebo. The duration of the 2 preventive-studies (PreD and GD) and the 2 interventive-studies (T2D) of the probiotic ranged from 10 to 16 weeks.

Results

pA1c® is safe in the EU (EFSA) and USA (GRAS) and prevents Diabetes onset. The normoglycemic activity of pA1c®, and the preliminary mechanism of action were established considering the integrated results in the insulin-signaling-pathway of C. elegans and mice. Mice supplemented with pA1c® were less likely to develop Diabetes by reducing fasting blood glucose and insulin resistance and by modulating the gut microbiota in all studies. pA1c® was found to be compatible with metformin. Long-term glycaemic regulation combined or solely with pA1c® was more effective than with metformin alone. Furthermore, a synergistic effect was observed combined with PC and BGC.

Conclusions

Studies suggest that pA1c® regulates blood sugar levels via multiple synergistic mechanisms acting together, from microbiome modulation to physiological changes. Thus, it could be considered as potential probiotic strain for the prevention and management of Diabetes-related conditions.